^
Association details:
| Biomarker: | SDC1 expression |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Drug: | carboplatin (Tubulin polymerization promoter) + paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Syndecan‑1 expression is an independent favourable prognostic marker in oesophageal adenocarcinoma and represents a potential therapeutic target
Published date:
07/04/2023
Excerpt:
Patients who received neoadjuvant CROSS (carboplatin, paclitaxel and intensity modulated radiotherapy) therapy and had CD138-positive tumors lived significantly longer (P=0.04)...In tumors without Her2/neu amplification, CD138 expression was associated with a longer OS (P=0.02)...This indicates that CD138 is also a predictive, therapeutically relevant biomarker.
DOI:
10.3892/ol.2023.13942
